Cargando…

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy

BACKGROUND: Circulating tumour DNA (ctDNA) analysis promises to improve the clinical care of people with cancer, address health inequities and guide translational research. This observational cohort study used ctDNA to follow 29 patients with advanced-stage cutaneous melanoma through multiple cycles...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Sandra, Blenkiron, Cherie, Stephens, Rosalie, Mathy, Jon A., Somers-Edgar, Tiffany, Rolfe, Gill, Martin, Richard, Jackson, Christopher, Eccles, Michael, Robb, Tamsin, Rodger, Euan, Lawrence, Ben, Guilford, Parry, Lasham, Annette, Print, Cristin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131510/
https://www.ncbi.nlm.nih.gov/pubmed/37099071
http://dx.doi.org/10.1007/s40291-023-00651-4
_version_ 1785031192889786368
author Fitzgerald, Sandra
Blenkiron, Cherie
Stephens, Rosalie
Mathy, Jon A.
Somers-Edgar, Tiffany
Rolfe, Gill
Martin, Richard
Jackson, Christopher
Eccles, Michael
Robb, Tamsin
Rodger, Euan
Lawrence, Ben
Guilford, Parry
Lasham, Annette
Print, Cristin G.
author_facet Fitzgerald, Sandra
Blenkiron, Cherie
Stephens, Rosalie
Mathy, Jon A.
Somers-Edgar, Tiffany
Rolfe, Gill
Martin, Richard
Jackson, Christopher
Eccles, Michael
Robb, Tamsin
Rodger, Euan
Lawrence, Ben
Guilford, Parry
Lasham, Annette
Print, Cristin G.
author_sort Fitzgerald, Sandra
collection PubMed
description BACKGROUND: Circulating tumour DNA (ctDNA) analysis promises to improve the clinical care of people with cancer, address health inequities and guide translational research. This observational cohort study used ctDNA to follow 29 patients with advanced-stage cutaneous melanoma through multiple cycles of immunotherapy. METHOD: A melanoma-specific ctDNA next-generation sequencing (NGS) panel, droplet digital polymerase chain reaction (ddPCR) and mass spectrometry analysis were used to identify ctDNA mutations in longitudinal blood plasma samples from Aotearoa New Zealand (NZ) patients receiving immunotherapy for melanoma. These technologies were used in conjunction to identify the breadth and complexity of tumour genomic information that ctDNA analysis can reliably report. RESULTS: During the course of immunotherapy treatment, a high level of dynamic mutational complexity was identified in blood plasma, including multiple BRAF mutations in the same patient, clinically relevant BRAF mutations emerging through therapy and co-occurring sub-clonal BRAF and NRAS mutations. The technical validity of this ctDNA analysis was supported by high sample analysis–reanalysis concordance, as well as concordance between different ctDNA measurement technologies. In addition, we observed > 90% concordance in the detection of ctDNA when using cell-stabilising collection tubes followed by 7-day delayed processing, compared with standard EDTA blood collection protocols with rapid processing. We also found that the undetectability of ctDNA at a proportion of treatment cycles was associated with durable clinical benefit (DCB). CONCLUSION: We found that multiple ctDNA processing and analysis methods consistently identified complex longitudinal patterns of clinically relevant mutations, adding support for expanded clinical trials of this technology in a variety of oncology settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40291-023-00651-4.
format Online
Article
Text
id pubmed-10131510
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101315102023-04-27 Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy Fitzgerald, Sandra Blenkiron, Cherie Stephens, Rosalie Mathy, Jon A. Somers-Edgar, Tiffany Rolfe, Gill Martin, Richard Jackson, Christopher Eccles, Michael Robb, Tamsin Rodger, Euan Lawrence, Ben Guilford, Parry Lasham, Annette Print, Cristin G. Mol Diagn Ther Original Research Article BACKGROUND: Circulating tumour DNA (ctDNA) analysis promises to improve the clinical care of people with cancer, address health inequities and guide translational research. This observational cohort study used ctDNA to follow 29 patients with advanced-stage cutaneous melanoma through multiple cycles of immunotherapy. METHOD: A melanoma-specific ctDNA next-generation sequencing (NGS) panel, droplet digital polymerase chain reaction (ddPCR) and mass spectrometry analysis were used to identify ctDNA mutations in longitudinal blood plasma samples from Aotearoa New Zealand (NZ) patients receiving immunotherapy for melanoma. These technologies were used in conjunction to identify the breadth and complexity of tumour genomic information that ctDNA analysis can reliably report. RESULTS: During the course of immunotherapy treatment, a high level of dynamic mutational complexity was identified in blood plasma, including multiple BRAF mutations in the same patient, clinically relevant BRAF mutations emerging through therapy and co-occurring sub-clonal BRAF and NRAS mutations. The technical validity of this ctDNA analysis was supported by high sample analysis–reanalysis concordance, as well as concordance between different ctDNA measurement technologies. In addition, we observed > 90% concordance in the detection of ctDNA when using cell-stabilising collection tubes followed by 7-day delayed processing, compared with standard EDTA blood collection protocols with rapid processing. We also found that the undetectability of ctDNA at a proportion of treatment cycles was associated with durable clinical benefit (DCB). CONCLUSION: We found that multiple ctDNA processing and analysis methods consistently identified complex longitudinal patterns of clinically relevant mutations, adding support for expanded clinical trials of this technology in a variety of oncology settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40291-023-00651-4. Springer International Publishing 2023-04-26 2023 /pmc/articles/PMC10131510/ /pubmed/37099071 http://dx.doi.org/10.1007/s40291-023-00651-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Fitzgerald, Sandra
Blenkiron, Cherie
Stephens, Rosalie
Mathy, Jon A.
Somers-Edgar, Tiffany
Rolfe, Gill
Martin, Richard
Jackson, Christopher
Eccles, Michael
Robb, Tamsin
Rodger, Euan
Lawrence, Ben
Guilford, Parry
Lasham, Annette
Print, Cristin G.
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title_full Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title_fullStr Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title_full_unstemmed Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title_short Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
title_sort dynamic ctdna mutational complexity in patients with melanoma receiving immunotherapy
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131510/
https://www.ncbi.nlm.nih.gov/pubmed/37099071
http://dx.doi.org/10.1007/s40291-023-00651-4
work_keys_str_mv AT fitzgeraldsandra dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT blenkironcherie dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT stephensrosalie dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT mathyjona dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT somersedgartiffany dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT rolfegill dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT martinrichard dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT jacksonchristopher dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT ecclesmichael dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT robbtamsin dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT rodgereuan dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT lawrenceben dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT guilfordparry dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT lashamannette dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy
AT printcristing dynamicctdnamutationalcomplexityinpatientswithmelanomareceivingimmunotherapy